亚洲日韩欧美综合-亚洲日韩欧美一区二区在线-亚洲日韩欧美视频-亚洲日韩精品欧美一区二区-国产欧美日韩综合

會(huì)員登錄|免費(fèi)注冊(cè)|忘記密碼|管理入口 返回主站||保存桌面|手機(jī)瀏覽|聯(lián)系方式|購物車
企業(yè)會(huì)員第1年

萊佛士制藥技術(shù)有限公司  

醫(yī)藥中間體和原料藥;有機(jī)催化劑;提供國際水準(zhǔn)的綠色工藝開發(fā)、定制合成與生產(chǎn)等方面的服務(wù)

搜索
新聞中心
  • 暫無新聞
產(chǎn)品分類
聯(lián)系方式
  • 聯(lián)系人:莫先生
  • 電話:0752-5538396
  • QQ:2634038916
站內(nèi)搜索
 
榮譽(yù)資質(zhì)
  • 暫未上傳
友情鏈接
  • 暫無鏈接
1335210-23-5
單價(jià) 面議對(duì)比
詢價(jià) 暫無
發(fā)貨 廣東惠州市付款后3天內(nèi)
品牌 RAFFLES
規(guī)格 1-10g;100g;500g;1kg;10kg
純度 ≥98%
貨期 1-2 周
過期 長(zhǎng)期有效
更新 2016-08-15 10:26
 
詳細(xì)信息
 
中文名稱: DOLUTEGRAVIR 中間體
中文同義詞: DOLUTEGRAVIR 中間體;度魯特韋ME-N-4
英文名稱: 1-(2,2-diMethoxyethyl)-5-Methoxy-6-(Methoxycarbonyl)-4-oxo-1,4-dihydropyridine-3-carboxylic acid
英文同義詞: 1-(2,2-diMethoxyethyl)-5-Methoxy-6-(Methoxycarbonyl)-4-oxo-1,4-dihydropyridine-3-carboxylic acid;Dulotegravir Me-N-4
CAS號(hào): 1335210-23-5
分子式: C13H17NO8
分子量: 315.27598
EINECS號(hào): -0
相關(guān)類別: 原料藥中間體
Mol文件: 1335210-23-5.mol
DOLUTEGRAVIR 中間體
©2025 萊佛士制藥技術(shù)有限公司 版權(quán)所有   技術(shù)支持:化工網(wǎng)   訪問量:2805  
 
主站蜘蛛池模板: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |